Allogene announced a major pivot in its development strategy, shifting out of developing cema-cel in third-line LBCL and planning instead to develop it in the first line consolidation setting.
The move got mostly positive responses from analysts, given that it represents a larger market opportunity, especially as the third-line setting has become crowded with CAR-Ts and bispecifics.
The company is also planning a Phase I study of ALLO-329 in autoimmune disease, touting the potential of the anti-CD19 CAR-T’s underlying technology to reduce or eliminate the need for lymphodepletion.
Allogene also highlighted plans to develop cema-cel in CLL – where autologous CAR-Ts have had little success and allogeneic approaches may be more suitable – will continue to develop ALLO-316 in kidney cancer.

Allogene’s Cema-Cel Goes Express As Company Shifts To First-Line LBCL

Autoimmune CAR-T Could Sidestep Lymphodepletion